Johnson & Johnson unit Janssen
Global Services said on Saturday that it does not intend to make
an offer for biotech company Horizon Therapeutics Plc. Last month, Horizon. | December 3, 2022
The high cost of acquiring treatment in developing as well as developed regions is challenging the growth of the Bleeding Disorder Therapeutics industry.